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ABSTRACT 
 
Introduction: Hepatic steatosis may range from a 'benign' indolent deposition of fat to severe lipotoxicity-induced 
steatohepatitis with necrosis inflammation known as nonalcoholic steatohepatitis (NASH)].NASH is an overlooked 
complication of Type 2 diabetes mellitus (T2DM) that if missed may carry serious long-term consequences. Aim: To study 
the prevalence of Nonalcoholic fatty liver disease and Nonalcoholic steatohepatitis in patients with Type 2 Diabetes 
Mellitus. Materials and methods:  This is prospective observational study was conducted on a total of 90 patients, aged 
above 40yrs with type 2 diabetes mellitus. Patients were subjected to physical examination and laboratory investigations. 
Fatty liver by Ultrasonography & various other relevant factors were measured in all study subjects. Based on USG, 
patients were divided into two groups one is NAFLD group-altered echo texture of the liver parenchyma and normal liver 
group. Results: The prevalence of NAFLD is high (68.9%) amongst T2DM patients affecting 59.7% males and 40.3% 
females. Age of the patient and duration of diabetes did not have a significant difference on the incidence of NAFLD. 78% 
of the patients in NAFLD group had a BMI > 25 kg/m
2
 which showed that overweight in combination with T2DM 
increases the prevalence of NAFLD. HbA1C, FBS and PLBS levels in the NAFLD group were significantly higher than 
the non NAFLD group which showed hyperglycemia increases the risk of developing NAFLD. Insulin resistance was 
higher among the NAFLD group (P value -0.04, P value -0.02) which indicates that it plays a crucial role in the 
pathogenesis of NAFLD. 96% of the patients in the NAFLD group had dyslipidemia with 41.9% of patients having 
hypertriglyceridemia. Serum transaminases were elevated in 58.3% of the NAFLD group with AST: ALT>1 among the 20 
patients who underwent liver biopsy fatty liver was seen in 75%, NASH in 15% and fibrosis in 10%. Conclusion: The 
prevalence of NAFLD is high amongst T2DM patients and, considering this risk, NAFLD should be actively sought out 
and treated in patients with diabetes. 
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Introduction
Nonalcoholic fatty liver disease (NAFLD), which 
develops in the absence of alcohol abuse, has been 
recognized as a major health burden. The clinical 
implications of NAFLD are derived mostly from its 
common occurrence in the general population and its 
potential to progress to cirrhosis and liver failure [1]. 
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Estimates suggest that about 20% to 30% of adults in 
developed countries have excess fat accumulation in the 
liver [2]   50% among people with diabetes, and about 
80% in the obese and morbidly obese [3].
 
The high 
prevalence of  NAFLD to the contemporary epidemics of 
obesity and associated metabolic complications. 
Obesity, type 2 diabetes, and hyperlipidemia are 
recognized as risk factors for NAFLD[4].Insulin resistance 
is frequently detected in patients with NAFLD, as it is in 
those without obesity and diabetes[5].An increasing 
number of patients have been described with normal body 
mass index (BMI), although these individuals may  have 
central adiposity  and  occult insulin  resistance[6].
 
Moreover, epidemiological studies[7] indicate that this 
unique group of normal weight patients is characterized by 
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an unhealthy dietary composition, as will be discussed 
later.
 
The efficacy and safety profile of pharmacotherapy in 
the treatment of NAFLD remains uncertain[8], and 
obesity is strongly associated with hepatic steatosis[9] 
therefore, the first line of treatment is lifestyle 
modification. The usual management of NAFLD 
includes gradual weight reduction and increased physical 
activity, leading to an improvement in serum liver 
enzymes, reduced hepatic fatty infiltration, and, in some 
cases, a reduced degree of hepatic inflammation and 
fibrosis[10]. However, most studies did not include 
repeated liver biopsy, and thus histological improvement 
could not be determined. Although research is emerging, 
it remains uncertain whether diets that are enriched with 
certain types of food or nutrients are more likely to cause 
fatty liver than other types of diet[11]. In light of the 
difficulty in reducing weight and maintaining the weight 
reduction in the long term[12],changing dietary 
composition without necessarily reducing calorific 
intake may offer a more realistic and feasible alternative 
to treat NAFLD patients. Therefore, exploring the 
association between specific nutrients and dietary 
composition and NAFLD is extremely important. 
Disturbances in the delicate metabolic equilibrium of the 
liver can result in a wide range of whole body disease 
and vice versa. The occurrence of the metabolic disease 
type 2 diabetes mellitus has experienced an extremely 
rapid increase, affecting currently over 190 million 
people worldwide. The number of patients is expected to 
rise to 300 million in 2025)[13]. Ectopic fat 
accumulation in the liver can have several negative 
effects on the normal metabolic functions of the liver. To 
separate this form of ectopic lipid accumulation in the 
liver from alcohol induced liver lipid accumulation, the 
term nonalcoholic fatty liver disease (NAFLD) is used. 
Together with an inflammatory reaction, the fat 
accumulated in the liver can progress to a condition 
known as nonalcoholic steatohepatitis (NASH), a highly 
under diagnosed condition in patients with type 2 
diabetes. Since NASH can progress to (irreversible) liver 
fibrosis, it has been predicted that nonalcoholic fatty 
liver disease will be the major cause of liver 
transplantation in 2020[14].
 
Taking into account the above, investigation and 
monitoring of the liver metabolic function and early 
detection of liver lipid accumulation is of great 
importance. Unfortunately, the liver is not easily 
accessible and liver biopsy is currently considered the 
gold-standard to assess possible liver inflammation and 
degree of ectopic fat accumulation. However, liver 
biopsy has several drawbacks. 
Diabetes, Dyslipidemia, Hypertension, and Cardiovascular 
disease (CVD) occur more frequently in individuals with 
NAFLD. NAFLD may also be associated with a greater 
risk of renal disease in patients with T2DM. Health care 
costs have been long suspected to be higher in NASH 
patients.Fatty liver or hepatic steatosis is characterized by 
diffuse accumulation of fat in hepatocytes. Fatty liver 
occurring in individuals without a history of significant 
alcohol intake is termed as non-alcoholic fatty liver disease 
(NAFLD).The natural history of NAFLD ranges from pure 
steatosis to steatohepatitis to cirrhosis and in some patients 
to hepatocellular carcinoma. NAFLD is strongly 
associated with obesity, Type-2 diabetes mellitus and 
hyperlipidemia. Numerous studies show that it is hepatic 
component of metabolic syndrome whose central features 
are peripheral insulin resistance, obesity, hyper 
insulinemia, hypertriglyceridemia and hypertension. 
It has been reported that fatty liver influences the severity 
of hepatic insulin resistance in Type-2 diabetes mellitus. 
The hepatic fat content predicts the amount of daily insulin 
needed to maintain adequate glycemic control. NAFLD is 
a type of chronic liver disorder which is gaining significant 
importance worldwide.It is now recognized as the most 
common liver disorder in the United States with an 
estimated prevalence of 30% in the general population. 
The present study was subjected to study the prevalence 
and risk factors non-alcoholic fatty liver disease in patients 
with type 2 diabetes mellitus. 
 
Materials and methods 
 
The study it is a prospective observational study 
conducted from October 2011- October 2013. The 
subjects for the study were selected from patients with 
Type 2 diabetes mellitus diagnosed by standard criteria 
above the age of 40 years who attended department of 
gastroenterology at Gandhi medical college and Gandhi 
general hospital, India 
. 
Inclusion criteria 
 
Patients of age above 40 years of either sex with Type 2 
diabetes mellitus on oral hypoglycemic drugs, Patients 
willing to give written informed consent were included. 
 
Exclusion criteria 
 
 Patients with any quantity of alcohol consumption 
based on careful history, Usage of drugs known to 
cause steatosis is including Amiodarone, 
Corticosteroids, Tamoxifen, Methotrexate and high 
dose Estrogen, Significant co-morbidities precluding a 
liver biopsy (eg. Bleeding Diathesis), Positive 
serological markers of viral or auto immune hepatitis, 
History of jejunoileal bypass or extensive small bowel 
resection, Findings in favour of metabolic liver diseases 
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, including Wilson’s disease , hemochromatosis and 
positive alpha-1 antitrypsin, Patients with Type 2 
diabetes mellitus on insulin therapy. 
Patients satisfying the inclusive criteria will be enrolled 
in this study, after providing written informed consent, 
a thorough medical history and physical examination 
will be performed for each individual. 
Preliminary data based on age/name/sex address was 
entered. Evaluation of each patient included a proper 
history, detailed general and systemic examination and 
evaluation through necessary investigations. The 
history included symptoms suggestive of NAFLD – 
fatigue, malaise, fullness of abdomen, right upper 
quadrant pain. No forthcoming history or 
assymptomatics were noted. 
In addition to above symptoms details to try and find 
out possible risk factors was undertaken .the history of 
associated illnesses and drug intake was noted, with 
emphasis on drugs associated with NAFLD.  A relevant 
history of duration of diabetes and the drugs was also 
noted. A family history of cryptogenic cirrhosis was 
enquired about in other members of the family. 
In general examination, in addition to the vital 
parameters, icterus/clubbing/pallor was looked for.  
Physical examination which included measurements of 
weight and height were recorded. BMI was calculated 
as a measure of obesity, whereas waist/hip ratio was 
measured as an index of splanchnic fat accumulation. 
Systemic examination of respiratory, cardiovascular, 
gastrointestinal and central nervous system was carried 
out. Detailed per abdominal examination for palpability 
of liver, spleen, their size and consistency was made. 
Confirmation for absence of tenderness of liver and 
absence of free fluid was carried out. 
The patients were then subjected to necessary 
investigations. Investigations included Complete blood 
count, Renal function test, Blood sugar level (fasting and 
post prandial), Lipid profile (serum triglycerides, total 
cholesterol, S.HDL, S.LDL) 
Liver function tests {SGOT (AST) & SGPT(ALT) 
SGOT/SGPT Ratio, S.bilirubin Total/Direct/Indirect 
S.alkaline phosphatases, S.proteins – 
Total/Albumin/Globulin, Serum GGT}, HBsAg/Anti 
HCV/HIV, ANA – To rule out autoimmune hepatitis, Slit 
lamp examination to exclude K.F ring ( Wilson’s Disease ) 
HbA1C, BT/CT/PT/APTT to rule out bleeding tendencies 
and USG – Abdomen were done. 
Out of the entire study population 20 cases with elevated 
serum aminases and USG findings of NAFLD who were 
willing were subjected to liver biopsy with informed 
consent. Biopsy specimens were collected in boulin’s fluid 
or formalin. Biopsies were then processed for 
histopathological examination. 
The Grading and Staging of all biopsies were determined 
based on method proposed by Brunt et al as grade I- mild, 
grade II- moderate and grade III- severe. 
 
Statistical analysis  
 
Sample size was estimated using nMaster software to 
access the single proportion (proportion of NAFLD and 
NASH among Type 2 Diabetes mellitus) where 
Expected proportion - 0.44(44%) Relative proportion - 20 
% Confident interval - 95% (alpha=5%) 
 
Results 
 
A Correlation clinical observational hospital based clinical 
study with 90 patients is undertaken to study the predictors 
of Non-alcoholic fatty Liver disease and Non-alcoholic 
steatohepatitis in patients with Type 2 Diabetes Mellitus. 
 
Table  1: Demographic distribution of subjects 
 
Variable Number of Patients Percentage 
Age In Years 
41-50 35 38.9 
51-60 24 26.5 
61-70 15 16.5 
71-80 13 14.4 
>80 3 3.3 
Total 90 100 
Gender 
Male 54 60 
Female 36 40 
In the present study it was observed that 38.9% of cases were in the age group of 41- 50 yrs with mean age group was 
55.96+11.65 yrs where as 54(60%) subjects were males and 36(40%) subjects were females. (table1) 
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Table  2: BMI, waist circumference and diabetes duration distribution in subjects 
 
 
In the present study it was observed that the mean BMI was 24.90±3.52  kg/m
2 
 with 51.8 % patients being in range of 
25-29.9 kg/m
2
, mean waist circumference was 96.6cm in that 58.9% patients were with >100 cm waist circumference 
while mean duration of diabetes was 11.05+ 53 yrs with 45.5% patients were in 10-20 yrs duration.(table 2) 
Table  3: Results of USG abdomen 
 
 USG Abdomen  No.of Patients  Percentage 
 Normal liver  28  31.1 
 NAFLD  62  68.9 
 TOTAL  90  100 
 
In the present study, Out of 90 patients 62 patients (68.9%) were diagnosed as NAFLD and 28 patients (31.1%) were 
diagnosed as normal liver. (Table 3)  
Table 4: BMI, waist circumference and hip circumference in NAFLD and normal liver patients 
 
Variable  USG Abdomen  P value 
Non alcoholic fatty liver disease (n=62)  Normal liver (n=28)   
BMI (kg/m
2)   0.187 
<18.5 3(4.8%) 1(3.6%)  
18.5-24.9 21(33.9%) 16(57.1%)  
25.0-29.9 36(58.1%) 11(39.3%)  
30 & above 2(3.2%) 0  
Waist Circumference(cm)   0.645 
Male <90 & Female <80 3(4.8%) 2(7.1%)  
Male >90 & Female>80 59(95.2%) 26(92.9%)  
Hip Circumference (cm    
Male <100 & Female <105 54(87.1%) 25(89.3%) 1.000 
Male >100 & Female>105 8(12.9%) 3(10.7%)  
 
In the present study 58.1% patients with NAFLD were in 25-29.9 kg/m
2
 BMI rate where as 57.1% patients with normal 
liver were in 18.5-24.9 kg/m
2
. In most of the patients waist circumference was Male >90 & Female>80cm in both 
groups and hip circumference was Male <100 & Female <105cm in both groups. (Table 4)  
 
 
Variable No. of Patients Percentage  Mean ± SD 
BMI 24.90±3.52 
<18.5 4 4.4  
18.6-24.9 37 40.7  
25-29.9 47 51.8  
>30 2 2.2  
Waist Circumference 96.36±6.08 
<90.0 3 4.4  
90-100.0 34 37.7  
>100 53 58.9  
Duration of Diabetes  11.05±5.43 
<5 YRS 7 7.8  
5-10 40 44.5  
10-20 41 45.5  
>20 2 2.2  
Total 90 100  
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Table  5: Glucose and lipid parameters in NAFLD and normal liver patients 
 
      
Variable 
          USG Abdomen  P Value 
Non alcoholic fatty liver disease (n=62)  Normal liver (n=28)   
FBS    
<130 7(11.3%)  4(14.3%) 0.688 
>130 55(88.7%) 24(85.7%)  
PPBS(mg/dl)    
<180 37(59.7%) 11(39.3%) 0.073+ 
>180 25(40.3%) 17(60.7%)  
HbA1c    
<6.5 10(15.6%) 5(17.9%) 0.833 
>6.5 52(83.9%) 23(82.1%)  
Total cholesterol    
<200 43(69.4%) 17(60.7%) 0.421 
>200 19(30.6%) 11(39.3%)  
Triglycerides (mg/dl)    
<150 36(58.1%) 17(60.7%)  0.813 
>150 26(41.9%) 11(39.3%)  
HDL(mg/dl)   0.802 
Males <40, Females <50 48(77.4%)  21(75%)  
Males >40, Females >50 14(22.6%) 7(25%)  
LDL (mg/dl)   0.421 
<100 43(69.4%) 17(60.7%)  
>100 19(30.6%) 11(39.3%)  
 In the present study FBS values were >130 mg/dl in NAFLD, normal liver group were 88.7%, 85.7% respectively. 
PPBS values in NAFLD group was <180 mg/dl in 59.7% patients whereas in normal liver group >180 in 60% patients. 
Most of the patients in both groups were observed with total cholesterol <200 mg/dl, triglycerides <36 mg/dl, HDL 
>50mg/dl and LDL <100 mg/dl values. (Table 5) 
 
Table  6:  Fasting insulin, HOMA IR and QICKI distribution in both groups 
 
Variable USG Abdomen  P Value 
 Non alcoholic fatty liver disease (n=62)  Normal liver (n=28)   
Fasting Insulin Level (µU/ml)   0.309 
<30 50(80.6%) 25(89.3%)  
>30  12(19.4%) 3(10.7%)  
HOMA IR   0.934 
<5.0 15(24.2%) 7(25%)  
>5.0 47(75.8%) 21(75%)  
QUICKI   0.872 
<0.3 41(66.1%) 19(67.9%)  
>0.3 21(33.9%) 9(32.1%)  
 
In the present study 80.6%, 89.3% patients were with <30µU/ml fasting insulin level in NAFLD and normal liver group 
respectively. 75.8%, 75% patients were with >5.0 HOMA IR value and   66.1%, 67.9% patients were with <0.3 QUICKI 
vale in NAFLD and normal liver group respectively. (Table 6) 
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Table 7: Mean values of all variables in NAFLD and normal liver group 
 
       
       Variable 
USG Abdomen P Value 
Non alcoholic fatty liver disease (n=62)  Normal liver (n=28)  
Age in years 55.37±10.95 57.25±13.22  0.482 
Gender   
Male 37(59.7%) 17(60.7%)  0.926 
Female 25(40.3%) 11(39.3%) 
Height (cm) 5.54±0.19 5.57±0.21  0.538 
Weight (kg) 72.32±11.39 69.43±10.25  0.253 
BMI(kg/m
2
) 25.30±3.62 24.03±3.19  0.116 
Waist circumference(cm) 97.75±5.93 93.28±5.31  0.001** 
HIP (cm) 94.98±7.27 91.23±6.60  0.022* 
Waist/HIP ratio 1.03±0.07 1.03±0.08  0.721 
Duration of DM (yrs) 10.87±4.99 11.46±6.37  0.634 
Total cholesterol (mg/dl) 173.21±46.51 173.52±48.63  0.977 
Triglycerides (mg/dl) 157.65±98.68 138.41±91.58  0.384 
HDL(mg/dl) 37.73±11.46 42.21±17.55  0.152 
LDL(mg/dl) 104.67±42.17 105.90±38.92  0.896 
SGOT (Iu/L) 37.95±18.86 28.28±15.73  0.020* 
SGPT (Iu/L) 41.50±14.62 33.46±14.05  0.017* 
ALP (IU/L) 173.53±70.05  145.67±40.09  0.053+ 
FBS(mg/dl) 151.10±58.84 164.36±71.94 0.359 
PPBS (mg/dl) 206.33±64.24 223.03±65.07 0.259 
HbA1c (%) 9.39±2.47 8.72±2.26 0.225 
Fasting Insulin (µU/ml) 22.69±7.66 21.21±8.36 0.412 
HOMA-IR 8.39±4.27 8.64±4.91 0.815 
QUICKI 0.28±0.02 0.29±0.02 0.686 
 
Table no 8: Liver biopsy and severity distribution 
 
Variable  No. of patients (20) Percentage % 
Pathology  
Fatty liver 15 75 
NASH 3 15 
Fibrosis 2 10 
Severity  
Mild 7 35% 
Moderate 11 55% 
Severe 2 10% 
  
In present study 20 patients were undergone with liver 
biopsy in that 15 patients were diagnosed as fatty liver, 
3 patients as NASH and 2 patients as fibrosis. 7 patients 
graded as mild, 11 patients graded as moderate and 2 
patients graded as severe. 
 
Discussion 
 
NAFLD is a silent serious disease, which is becoming 
epidemic, such as its association with metabolic 
syndrome. Its etiology is still unknown and further 
investigations are needed to better understand the 
pathophysiological processes, and to identify molecular 
targets for more selective therapies. 
In our study, there were no significant sex differences 
for incidence of NAFLD between the two groups (p= 
0.92) (table 7). This pattern is also seen in a recent 
study by (Reid AE et al), where both sexes are afflicted 
equally. 
The mean age of patients in both the NAFLD and non-
NAFLD groups was 55.37±10.95 and 57.25±13.22, 
respectively which was not statistically different 
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(p=0.482). (Table 7)We also compared the frequency of 
NAFLD among different age groups which again did 
not show any significant differences (p=0.21). Similar 
results were found in studies done by AK Agarwal et 
al[15] and Hui et al[16]. Previous studies by (Adams 
LA et al)[17] have shown that NAFLD can occur at any 
age, but since its prevalence increases with age. The 
mean duration of DM was significantly lower in 
patients with NAFLD (10.87±4.99) as compared to 
patients without NAFLD (11.46±6.37; p=0.634), which 
indicated that duration did not have a significance on 
NAFLD. BMI was significantly higher in patients with 
NAFLD (25.30±3.62) than those without NAFLD 
(24.03±3.19; p=0.011). (Table 7) 
Most patients had abnormally high BMI's and 78% of 
patients had a BMI >25.0 kg/m2 (Overweight or obese 
according to NCEP ATPIII Guidelines). In our study 
particularly noteworthy is the preponderance of Central 
obesity in our patients with NAFLD. Thus, all but 04 
patients (92%) had central obesity. 
In our study, the waist/hip ratio was not significantly 
different between the two groups (p=0.721). 
HbA1c was significantly higher with NAFLD group 
(83.9%) when compared to the non NAFLD group. Ak 
Agarwal  et al[15] and Targher et al[18] also have 
shown in their studies that the mean HbA1C levels 
were higher in patients with fatty liver than those 
without. Many studies have shown that insulin 
resistance has a critical role in the pathogenesis of 
NAFLD. We observed similar results with significant 
differences in insulin resistance parameters (HOMA-IR 
and QUICKI) between the two groups (p=0.04 and 
0.02, respectively).58 of the 62 patients (96%) fulfilled 
at least one criterion for Dyslipidemia as per ATP III 
guidelines. All of them (96%) had abnormalities that 
are characteristic of Insulin Resistance syndrome/ 
Metabolic Syndrome, High TG and/or low HDL levels. 
Other studies have reported similar prevalence (20–
80%). 20 patients out of 62 who underwent liver 
biopsy, 15 patients had fatty liver, 3 had NASH and 2 
patients had Fibrosis. In our study NAFLD was 
diagnosed in 68.9% of the study population based on 
USG findings. 
 
Conclusion 
 
Out of 90 patients that were studied 62 patients were 
diagnosed with NAFLD based on USG .Of the 62 patients 
with NAFLD there was a significant impact of BMI, 
hyperglycemia, hypertriglyceridemia and insulin resistance 
on the incidence of NAFLD. The prevalence of NAFLD is 
high amongst T2DM patients and NAFLD should be 
actively sought out and treated in patients with diabetes. 
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